EEG / EMG in Massachusetts

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

Ives EEG Solutions, Inc. manufactures and supplies EEG electrodes and electrode harness systems for clinical, research, and veterinary applications. Founded in 1995, the company specializes in disposable conductive plastic electrodes (DCPE), electrode harnesses, subdermal wire electrodes, and MR/CT-compatible electrode kits. Products are designed for intensive care units (ICUs), epilepsy monitoring units (EMUs), and long-term EEG monitoring. The company emphasizes skin-safe, child-friendly electrode designs to minimize skin breakdown in neonates and sensitive-skin patients. All products are manufactured to support EEG accuracy and cost-effectiveness for hospitals and clinical centers. The company serves hospitals, clinics, research institutions, and veterinary centers globally. Ives EEG Solutions is preferred by EEG technologists for product quality, ease of use, and customer service. The firm also offers free product samples and expert consultation services to support customer needs.

Diagnosys LLC is a specialized manufacturer of visual electrophysiology test systems for both preclinical research and clinical ophthalmology practice. With over 40 years of market presence, the company designs and manufactures hardware and software for measuring visual function through electroretinography (ERG), pattern electroretinography (PERG), visually evoked potentials (VEP), and related electrophysiological testing modalities. The company's product portfolio spans three major categories: (1) Preclinical systems, including the proprietary Celeris® platform for rodent testing with dual-function stimulator-electrodes and ERG solutions for small to large animals; (2) Clinical visual function test systems encompassing visual electrophysiology, visual psychophysical testing, objective acuity measurement, and pupillometry; and (3) Trial services including study setup assistance, operator training, and quality assurance data review for multi-site clinical research. Diagnosys serves a global customer base that includes leading academic medical centers, eye institutes, and specialty ophthalmology practices such as Mayo Clinic, Bascom Palmer Eye Institute, Cleveland Clinic, Moorfields Eye Hospital, and Wilmer Eye Institute. The systems are used across multiple ophthalmology subspecialties: retina (inherited retinal diseases), glaucoma, pediatric ophthalmology, and neuro-ophthalmology. The company also actively supports clinical trial infrastructure with 35+ years of trial services experience. Key capabilities include in-house hardware and software design, patented and trademarked platforms, and extensive clinical validation across academic and research institutions worldwide. The company participates in major scientific conferences (ARVO, Society for Neuroscience) and provides continuing education webinars on visual electrophysiology methodology.

Cumulus Neuroscience develops NeuLogiq®, a medical-grade, at-home digital data collection and analytics platform for functional brain health monitoring and central nervous system (CNS) disease management. The platform combines a 510(k)-cleared novel EEG headset with tablet-based cognitive, mood, language, and sleep assessments, synced to cloud-based machine learning analytics. NeuLogiq enables frequent longitudinal monitoring in clinical and home settings, designed to address challenges in CNS drug discovery including late diagnosis, patient stratification, and treatment monitoring. The company serves pharmaceutical companies conducting clinical trials through its Cumulus Pharma Advisory Group (CPAG), a paid-in consortium that includes ten major global pharmaceutical companies: Biogen, GSK, Pfizer, Eli Lilly, Takeda, Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche, and J&J Innovative Medicine. Several CPAG members have active studies using the NeuLogiq Platform. The platform assesses discrete brain functions including working memory, episodic memory, executive function, decision-making, neuronal integrity, network connectivity, emotional bias, speech characteristics, and sleep metrics. The company employs approximately 30 engineers, scientists, and business professionals, backed by experienced life science and technology investors including the Dementia Discovery Fund, as well as UK and EU innovation agencies. Regulatory clearance includes FDA 510(k) for the EEG headset. NeuLogiq integrates third-party validated algorithms for facial expression recognition, language analysis, and sleep staging.

machineMD AG is a medical device company founded at the University Hospital of Bern, Switzerland, specializing in non-invasive neuroophthalmological diagnostic equipment. The company develops neos®, a proprietary neurophthalmoscope platform designed for automated, quantitative assessment of eye movements, pupils, and visual fields. neos® enables standardized, objective measurement of neuroophthalmological function across primary, secondary, and tertiary care settings, reducing operator variability and extending specialist-level diagnostic capability to underserved clinical environments. The platform incorporates quantitative pupillometry and oculometric analysis with demonstrated clinical applications across neurological and ophthalmological indications including multiple sclerosis, myasthenia gravis, Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, age-related macular degeneration, and other neurodegenerative and neuro-ophthalmological conditions. machineMD operates facilities in Bern, Switzerland (headquarters at Weyermannsstrasse 36, 3008 Bern) and Cambridge, Massachusetts (1 Broadway, Cambridge, MA 02142). The company maintains active clinical partnerships with major Swiss academic hospitals including University Hospital Lucerne (LUKS), Inselspital Bern, and Universitätsspital Zürich, and international collaborations. Regulatory pathway and specific FDA/CE certification status not detailed on accessible site content.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

Delsys Inc. is a 30-year-old Massachusetts-based manufacturer of advanced wearable electromyography (EMG) systems and sensors for research, clinical diagnostics, and rehabilitation. The company specializes in wireless, real-time surface EMG technology with proprietary sensor designs and communication protocols optimized for human movement analysis, motor control research, neuromuscular physiology, and neurorehabilitation applications. Their primary product line—Trigno—comprises multiple system configurations (Centro for research-grade applications, Lite for entry-level systems, Link for integrated multimodal data acquisition, and HDsEMG for high-density motor unit analysis). Individual EMG sensors (Avanti, Mini, Duo, Quattro, Snap Lead) and auxiliary modules (Analog Adapter, FSR Adapter, Goniometer, Load Cell, EKG Biofeedback) enable customizable system builds. High-density EMG sensors (Galileo, Maize) support advanced motor unit decomposition and motor control studies. The Trigno ecosystem integrates with external research tools via a documented API and proprietary software (EMGworks, Trigno Discover, NeuroMap). Delsys serves academic institutions, medical research labs, rehabilitation facilities, exoskeleton/wearable robotics developers, and clinical diagnostics centers globally. Products emphasize low-noise signal acquisition, 40+ meter wireless range, intuitive data visualization and analysis workflows, and expandable architecture. The company provides remote and on-site training, technical support, and system integration services.

Jali Medical is a leading U.S. distributor of neuromodulation devices and wearable neurotechnologies, headquartered in Framingham, Massachusetts. Founded in 1991 with over 30 years of experience, the company specializes in non-invasive brain stimulation systems for neuroscience research and clinical applications. Jali Medical distributes FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy systems for treating Major Depressive Disorder, along with advanced electroencephalography (EEG) systems, transcranial direct current stimulation (tDCS/tACS) devices, electromyography (EMG) systems, and neuronavigation equipment. The company serves academic institutions, research centers, hospitals, and clinicians nationwide, providing precision-engineered neurotechnology coupled with comprehensive scientific support. Jali Medical offers flexible leasing options for TMS therapy systems and in-person product demonstrations to facilitate clinical adoption and research innovation in neurophysiology and behavioral health applications.

Cognision, operating as Neuronetrix Solutions, LLC, is an FDA-cleared medical technology company specializing in advanced EEG/ERP systems for objective evaluation of cognitive function. Founded in 2003, the company develops brain-based biomarker solutions for clinical assessment and pharmaceutical research. The COGNISION® System features a user-friendly EEG/ERP device with a comfortable headset for point-of-care testing, generating intuitive clinical reports. The technology is validated for assessing concussion, mild traumatic brain injury (mTBI), dementia, Alzheimer's disease, and other cognitive disorders. Cognision serves healthcare systems, private practices, universities, and global clinical trial sponsors, providing objective physiological measures of cognitive function for clinicians, researchers, and pharmaceutical companies conducting CNS drug development studies.